PMID- 33979117
OWN - NLM
STAT- MEDLINE
DCOM- 20220125
LR  - 20220125
IS  - 0890-9091 (Print)
IS  - 0890-9091 (Linking)
VI  - 35
IP  - 5
DP  - 2021 May 12
TI  - Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community 
      Physicians.
PG  - 244-248
LID - 10.46883/ONC.2021.3505.0244 [doi]
AB  - Background: Pancreatic adenocarcinoma (PDAC) is relatively rare but highly 
      aggressive, with most patients diagnosed once they have metastatic or locally 
      invasive disease. Molecular profiling is being explored as a tool for selecting 
      patients for targeted therapy clinical trials and for assessing whether targeted 
      therapies may be effective in PDAC. Whether molecular profiling is being 
      performed at both academic and community oncology clinics has yet to be examined. 
      Here, we characterized the molecular profiling practice patterns in patients with 
      PDAC in academic versus community practices in Denver, Colorado. Methods: We 
      retrospectively reviewed records of all patients with refractory, metastatic PDAC 
      who were referred to a tertiary clinical trials drug development unit in Denver 
      between 2014 and 2019. Results: Of 77 patients, 41 (55%) were men with a mean age 
      of 65 years (SD, 9.3). Fifty-three patients (69%) were referred from the 
      community and 20 (26%) from academic centers; 4 (5%) were self-referred. A total 
      of 51% received profiling prior to referral; 29 of 50 (58%) were from the 
      community and 10 of 21 (47%) from academic settings. Guardant was the most 
      commonly ordered test (47 of 77; 61%); FoundationOne was the second most common 
      (40 of 77; 52%). Twenty-three of 77 patients (30%) received both Guardant and 
      FoundationOne testing, and 3 of 77 (4%) received Caris MI Profile. One patient 
      received a Mocha assay and another received Ascend/Clarient fluorescence in situ 
      hybridization (FISH). Four patients were self-referred, 2 of whom underwent both 
      Guardant and FoundationOne, 1 who underwent Guardant testing only, and 1 who did 
      not receive any molecular profiling testing. Conclusions: This study 
      characterizes molecular profiling practice patterns in individuals with advanced 
      PDAC who were referred to a tertiary clinical trials drug development unit. Both 
      academic and community physicians were found to order profiling about 50% of the 
      time. Further research is needed to determine impact on clinical trial enrollment 
      and detection of PDAC.
FAU - Chung, Christine
AU  - Chung C
AD  - Swedish Medical Center, Englewood, CO.
FAU - Galvin, Rachael
AU  - Galvin R
AD  - Swedish Medical Center, Englewood, CO.
FAU - Achenbach, Ella
AU  - Achenbach E
AD  - Sarah Cannon Research Institute at HealthONE, Denver, CO.
FAU - Dziadkowiec, Oliwier
AU  - Dziadkowiec O
AD  - Graduate Medical Education of HCA HealthCare, Denver, CO.
FAU - Sen, Shiraj
AU  - Sen S
AD  - Sarah Cannon Research Institute at HealthONE, Denver, CO.
LA  - eng
PT  - Journal Article
DEP - 20210512
PL  - United States
TA  - Oncology (Williston Park)
JT  - Oncology (Williston Park, N.Y.)
JID - 8712059
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adenocarcinoma/*genetics/pathology/therapy
MH  - Aged
MH  - Biomarkers, Tumor
MH  - Female
MH  - High-Throughput Nucleotide Sequencing/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Pancreatic Neoplasms/*genetics/pathology/therapy
MH  - Physicians/*statistics & numerical data
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Precision Medicine/statistics & numerical data
MH  - Retrospective Studies
MH  - Universities/*statistics & numerical data
EDAT- 2021/05/13 06:00
MHDA- 2022/01/27 06:00
CRDT- 2021/05/12 16:55
PHST- 2021/05/12 16:55 [entrez]
PHST- 2021/05/13 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
AID - 10.46883/ONC.2021.3505.0244 [doi]
PST - epublish
SO  - Oncology (Williston Park). 2021 May 12;35(5):244-248. doi: 
      10.46883/ONC.2021.3505.0244.